The nonmotor symptoms of Parkinson's disease-An overview

Movement Disorders

Volumn 25, Issue SUPPL. 1, 2010, Pages

  Lim, Shen Yang ^a,b   Lang, Anthony E ^a  

^a TORONTO WESTERN HOSPITAL   (Canada)

^b UNIVERSITY OF MALAYA   (Malaysia)

Author keywords

Nondopaminergic; Nonmotor; Parkinson's disease; Plasticity; Staging

Indexed keywords

CHOLINESTERASE INHIBITOR; CLOZAPINE; DOPAMINE; MODAFINIL; QUETIAPINE; ANTIPARKINSON AGENT;

ARTICLE; BRAIN DEPTH STIMULATION; DAYTIME SOMNOLENCE; DISEASE COURSE; DOPAMINE DYSREGULATION SYNDROME; HUMAN; IMPULSE CONTROL DISORDER; NEUROPATHOLOGY; NONMOTOR SYMPTOM; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOSIS; PUNDING; SYMPTOMATOLOGY; BEHAVIOR; COGNITIVE DEFECT; DISABILITY; LEWY BODY; METABOLISM; METHODOLOGY; NEUROPSYCHOLOGICAL TEST; PATHOLOGY; PATIENT ATTITUDE; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; QUALITY OF LIFE; REVIEW; SMELLING DISORDER;

ANTIPARKINSON AGENTS; BEHAVIORAL SYMPTOMS; COGNITION DISORDERS; DEEP BRAIN STIMULATION; DISABILITY EVALUATION; DOPAMINE; HUMANS; LEWY BODIES; NEUROPSYCHOLOGICAL TESTS; OLFACTION DISORDERS; PARKINSON DISEASE; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; SICK ROLE;

EID: 77953457744     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22786     Document Type: Article

References (128)

1. Levy G. The relationship of Parkinson disease with aging. Arch Neurol 2007; 64: 1242-1246.
2. Kempster PA, Williams DR, Selikhova M, Holton J, Revesz T, Lees AJ. Patterns of levodopa response in Parkinson's disease: a clinico-pathological study. Brain 2007; 130: 2123-2128.
3. Halliday G, Hely M, Reid W, Morris J. The progression of pathology in longitudinally followed patients with Parkinson's disease. Acta Neuropathol 2008; 115: 409-415.
4. Hely MA, Reid WGJ, Adena MA, Halliday GM, Morris JGL. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008; 23: 837-844.
5. Lang AE, Obeso JA. Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough. Lancet Neurol 2004; 3: 309-316.
6. Chaudhuri KR, Healy DG, Schapira AHV. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006; 5: 235-245.
7. Grosset D, Taurah L, Burn DJ, et al. A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson's disease left untreated at diagnosis. J Neurol Neurosurg Psychiatry 2007; 78: 465-469.
8. Olson EJ, Boeve BF, Silber MH. Rapid eye movement sleep behavior disorder: demographic, clinical and laboratory findings in 93 cases. Brain 2000; 123: 331-339.
9. Abbott RD, Petrovitch H, White LR, et al. Frequency of bowel movements and the future risk of Parkinson's disease. Neurology 2001; 57: 456-462.
10. Abbott RD, Ross GW, Petrovitch H, et al. Bowel movement frequency in late-life and incidental Lewy bodies. Mov Disord 2007; 22: 1581-1586.
11. Kaufmann H, Nahm K, Purohit D, Wolfe D. Autonomic failure as the initial presentation of Parkinson disease and dementia with Lewy bodies. Neurology 2004; 63: 1093-1095.
12. Goldstein DS. Orthostatic hypotension as an early finding in Parkinson's disease. Clin Auton Res 2006; 16: 46-54.
13. Postuma RB, Lang AE, Massicotte-Marquez J, Montplaisir J. Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder. Neurology 2006; 66: 845-851.
14. Gao X, Chen H, Schwarzschild MA, et al. Erectile function and risk of Parkinson's disease. Am J Epidemiol 2007; 166: 1446-1450.
15. Schuurman AG, van den Akker M, Ensinck KTJL, et al. Increased risk of Parkinson's disease after depression: a retrospective cohort study. Neurology 2002; 58: 1501-1504.
16. Abbott RD, Ross GW, White LR, et al. Excessive daytime sleepiness and subsequent development of Parkinson disease. Neurology 2005; 65: 1442-1446.
17. Ponsen MM, Stoffers D, Booij J, van Eck-Smit BLF, Wolters EC, Berendse HW. Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann Neurol 2004; 56: 173-181.
18. Ross GW, Abbott RD, Petrovitch H, et al. Association of olfactory dysfunction with incidental Lewy bodies. Mov Disord 2006; 21: 2062-2067.
19. Haehner A, Hummel T, Hummel C, Sommer U, Junghanns S, Reichmann H. Olfactory loss may be a first sign of idiopathic Parkinson's disease. Mov Disord 2007; 22: 839-842.
20. Braak H, Del Tredici K, Rüb U, de Vos RAI, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197-211.
21. Braak H, de Vos RAI, Bohl J, Del Tredici K. Gastric α-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci Lett 2006; 396: 67-72.
22. Minguez-Castellanos A, Chamorro CE, Escamilla-Sevilla F, et al. Do α-synuclein aggregates in autonomic plexuses predate Lewy body disorders? A cohort study. Neurology 2007; 68: 2012-2018.
23. Hendricks JC, Morrisona AR, Manna GL. Different behaviors during paradoxical sleep without atonia depend on pontine lesion site. Brain Res 1982; 239: 81-105.
24. Uchiyama M, Isse K, Tanaka K, et al. Incidental Lewy body disease in a patient with REM sleep behavior disorder. Neurology 1995; 45: 709-712.
25. Mattila PM, Rinne JO, Helenius H, Dickson DW, Röyttä M. Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease. Acta Neuropathol 2000; 100: 285-290.
26. Apaydin H, Ahlskog JE, Parisi JE, Boeve BF, Dickson DW. Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol 2002; 59: 102-112.
27. Aarsland D, Perry R, Brown A, Larsen JP, Ballard C. Neuropathology of dementia in Parkinson's disease: a prospective, community-based study. Ann Neurol 2005; 58: 773-776.
28. Braak H, Rüb U, Jansen Steur ENH, Del Tredici K, de Vos RAI. Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 2005; 64: 1404-1410.
29. Langston JW. The Parkinson's complex: parkinsonism is just the tip of the iceberg. Ann Neurol 2006; 59: 591-596.
30. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988; 51: 745-752.
31. DelleDonne A, Klos KJ, Fujishiro H, et al. Incidental Lewy body disease and preclinical Parkinson disease. Arch Neurol 2008; 65: 1074-1080.
32. Lang AE, Lozano AM. Parkinson's disease: first of two parts. N Engl J Med 1998; 339: 1044-1053.
33. Kleiner-Fisman G, Fisman DN. Risk factors for the development of pedal edema in patients using pramipexole. Arch Neurol 2007; 64: 820-824.
34. Maricle RA, Valentine R, Carter J, Nutt JG. Mood response to levodopa infusion in early Parkinson's disease. Neurology 1998; 50: 1890-1892.
35. Tinazzi M, Del Vesco C, Fincati E, et al. Pain and motor complications in Parkinson's disease. J Neurol Neurosurg Psychiatry 2006; 77: 822-825.
36. Lim SY, Farrell MJ, Gibson SJ, Helme RD, Lang AE, Evans AH. Do dyskinesia and pain share common pathophysiological mechanisms in Parkinson disease? Mov Disord 2008; 23: 1689-1695.
37. Williams DR, Lees AJ. Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study. Lancet Neurol 2005; 4: 605-610.
38. Alves G, Larsen JP, Emre M, Wentzel-Larsen T, Aarsland D. Changes in motor subtype and risk for incident dementia in Parkinson's disease. Mov Disord 2006; 21: 1123-1130.
39. Fenelon G, Mahieux F, Huon R, Ziegler M. Hallucinations in Parkinson's disease-prevalence, phenomenology and risk factors. Brain 2000; 123: 733-745.
40. Holroyd S, Currie L, Wooten GF. Prospective study of hallucinations and delusions in Parkinson's disease. J Neurol Neurosurg Psychiatry 2001; 70: 734-738.
41. Goetz CG, Pappert EJ, Blasucci LM. Intravenous levodopa in chronically treated hallucinating Parkinson's disease patients: high dose pharmacological challenge does not precipitate visual hallucination. Neurology 1998; 50: 515-517.
42. Goetz CG, Fan W, Leurgans S, Bernard B, Stebbins GT. The malignant course of "benign hallucinations" in Parkinson disease. Arch Neurol 2006; 63: 713-716.
43. Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain 2002; 125: 391-403.
44. Papapetropoulos S, McCorquodale DS, Gonzalez J, Jean-Gilles L, Mash DC. Cortical and amygdalar Lewy body burden in Parkinson's disease patients with visual hallucinations. Parkinsonism Relat Disord 2006; 12: 253-256.
45. Calne DB, Brennan J, Spiers ASD, Stern GM. Hypotension caused by L-dopa. Br Med J 1970; 1: 474-475.
46. Kujawa K, Leurgans S, Raman R, Blasucci L, Goetz CG. Acute orthostatic hypotension when starting dopamine agonists in Parkinson's disease. Arch Neurol 2000; 57: 1461-1463.
47. Goldstein DS, Holmes CS, Dendi R, et al. Orthostatic hypotension from sympathetic denervation in Parkinson's disease. Neurology 2002; 58: 1247-1255.
48. Goldstein DS, Eldadah BA, Holmes C, et al. Neurocirculatory abnormalities in Parkinson disease with orthostatic hypotension: independence from levodopa treatment. Hypertension 2005; 46: 1333-1339.
49. Bonuccelli U, Lucetti C, Del Dotto P, et al. Orthostatic hypotension in de novo Parkinson disease. Arch Neurol 2003; 60: 1400-1404.
50. Biglan KM, Holloway RG, Jr, McDermott MP, Richard IH; Parkinson Study Group CALM-PD Investigators. Risk factors for somnolence, edema, and hallucinations in early Parkinson disease. Neurology 2007; 69: 187-195.
51. Ferreira JJ, Thalamas C, Montastruc JL, Castro-Caldas A, Rascol O. Levodopa monotherapy can induce "sleep attacks" in Parkinson's disease patients. J Neurol 2001; 248: 426-427.
52. Ondo WG, Vuong KD, Khan H, Atassi F, Kwak C, Jankovic J. Daytime sleepiness and other sleep disorders in Parkinson's disease. Neurology 2001; 57: 1392-1396.
53. Hobson DE, Lang AE, Wayne Martin WR, Razmy A, Rivest J, Fleming J. Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. JAMA 2002; 287: 455-463.
54. Garcia-Borreguero D, Schwarz C, Larrosa, O, de la Llave Y, de Yébenes JG. L-dopa-induced excessive daytime sleepiness in PD: a placebo-controlled case with MSLT assessment. Neurology 2003; 61: 1008-1010.
55. Razmy A, Lang AE, Shapiro CM. Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists. Arch Neurol 2004; 61: 97-102.
56. Gjerstad MD, Alves G, Wentzel-Larsen T, Aarsland D, Larsen JP. Excessive daytime sleepiness in Parkinson disease: is it the drugs or the disease? Neurology 2006; 67: 853-858.
57. Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 1999; 52: 1908-1911.
58. Ferreira JJ, Galitzky M, Montastruc JL, Rascol O. Sleep attacks and Parkinson's disease treatment. Lancet 2000; 355: 1333-1334.
59. Montastruc JL, Brefel-Courbon C, Senard JM, et al. Sleep attacks and antiparkinsonian drugs: a pilot prospective pharmacoepidemiologic study. Clin Neuropharmacol 2001; 24: 181-183.
60. Paus S, Brecht HM, Koster J, Seeger G, Klockgether T, Wullner U. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease. Mov Disord 2003; 18: 659-667.
61. Brodsky MA, Godbold J, Roth T, Olanow CW. Sleepiness in Parkinson's disease: a controlled study. Mov Disord 2003; 18: 668-672.
62. Avorn J, Schneeweiss S, Sudarsky LR, et al. Sudden uncontrollable somnolence and medication use in Parkinson disease. Arch Neurol 2005; 62: 1242-1248.
63. Tan EK, Lum SY, Fook-Chong SMC, et al. Evaluation of somnolence in Parkinson's disease: comparison with age- and sex-matched controls. Neurology 2002; 58: 465-468.
64. Arnulf I, Konofal E, Merino-Andreu M, et al. Parkinson's disease and sleepiness: an integral part of PD. Neurology 2002; 58: 1019-1024.
65. Kaynak D, Kiziltan G, Kaynak H, Benbir G, Uysal O. Sleep and sleepiness in patients with Parkinson's disease before and after dopaminergic treatment. Eur J Neurol 2005; 12: 199-207.
66. Andreu N, Chale J-J, Senard J-M, Thalamas C, Montastruc J-L, Rascol O. L-dopa-induced sedation: a double-blind cross-over controlled study versus triazolam and placebo in healthy volunteers. Clin Neuropharmacol 1999; 22: 15-23.
67. Ferreira JJ, Galitzky M, Thalamas C, et al. Effect of ropinirole on sleep onset: a randomized, placebo-controlled study in healthy volunteers. Neurology 2002; 58: 460-462.
68. Tandberg E, Larsen JP, Karlsen K. Excessive daytime sleepiness and sleep benefit in Parkinson's disease: a community-based study. Mov Disord 1999; 14: 922-927.
69. Korner Y, Meindorfner C, Moller JC, et al. Predictors of sudden onset of sleep in Parkinson's disease. Mov Disord 2004; 19: 1298-1305.
70. Menza M. The personality associated with Parkinson's disease. Curr Psychiatry Rep 2000; 2: 421-426.
71. Avanzi M, Baratti M, Cabrini S, Uber E, Brighetti G, Bonfa F. Prevalence of pathological gambling in patients with Parkinson's disease. Mov Disord 2006; 21: 2068-2072.
72. Voon V, Hassan K, Zurowski M, et al. Prospective prevalence of pathologic gambling and medication association in Parkinson disease. Neurology 2006; 66: 1750-1752.
73. Voon V, Hassan K, Zurowski M, et al. Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. Neurology 2006; 67: 1254-1257.
74. Pontone G, Williams JR, Spear Bassett S, Marsh L. Clinical features associated with impulse control disorders in Parkinson disease. Neurology 2006; 67: 1258-1261.
75. Weintraub D, Siderowf AD, Potenza MN, et al. Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol 2006; 63: 969-973.
76. Gallagher DA, O'Sullivan SS, Evans AH, Lees AJ, Schrag A. Pathological gambling in Parkinson's disease: risk factors and differences from dopamine dysregulation. Mov Disord 2007; 22: 1757-1763.
77. Driver-Dunckley E, Samanta J, Stacy M. Pathological gambling associated with dopamine agonist therapy in Parkinson's disease. Neurology 2003; 61: 422-423.
78. Tippmann-Peikert M, Park JG, Boeve BF, Shepard JW, Silber MH. Pathologic gambling in patients with restless legs syndrome treated with dopaminergic agonists. Neurology 2007; 68: 301-303.
79. Goodwin FK. Psychiatric side effects of levodopa in man. JAMA 1971; 218: 1915-1920.
80. Klos KJ, Bower JH, Josephs KA, Matsumoto JY, Ahlskog JE. Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy. Parkinsonism Relat Disord 2005; 11: 381-386.
81. Nutt JG. Continuous dopaminergic stimulation: is it the answer to the motor complications of levodopa? Mov Disord 2007; 22: 1-9.
82. Witjas T, Kaphan E, Azulay JP, et al. Nonmotor fluctuations in Parkinson's disease: frequent and disabling. Neurology 2002; 59: 408-413.
83. Giovannoni G, O'Sullivan JD, Turner K, Manson AJ, Lees AJ. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 2000; 68: 423-428.
84. Pezzella FR, Colosimo C, Vanacore N, et al. Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson's disease. Mov Disord 2005; 20: 77-81.
85. Evans AH, Lawrence AD, Potts J, Appel S, Lees AJ. Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease. Neurology 2005; 65: 1570-1574.
86. Evans AH, Pavese N, Lawrence AD, et al. Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol 2006; 59: 852-858.
87. Silveira-Moriyama L, Evans AH, Katzenschlager R, Lees AJ. Punding and dyskinesias. Mov Disord 2006; 21: 2214-2217.
88. Fernandez HH, Friedman JH. Punding on L-dopa. Mov Disord 1999; 14: 836-838.
89. Evans AH, Katzenschlager R, Paviour D, et al. Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome. Mov Disord 2004; 19: 397-405.
90. Lawrence AD, Evans AH, Lees AJ. Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry? Lancet Neurol 2003; 2: 595-604.
91. Cheng EM, Swarztrauber K, Siderowf AD, et al. Association of specialist involvement and quality of care for Parkinson's disease. Mov Disord 2007; 22: 515-522.
92. Hauser RA, Gauger L, Anderson WM, Zesiewicz TA. Pramipexole-induced somnolence and episodes of daytime sleep. Mov Disord 2000; 15: 658-663.
93. Merino-Andreu M, Arnulf I, Konofal E, Derenne JP, Agid Y. Unawareness of naps in Parkinson's disease and in disorders with excessive daytime sleepiness. Neurology 2003; 60: 1553-1554.
94. Lim SY, Evans AH, Miyasaki JM. Impulse control and related disorders in Parkinson's disease: review. Ann NY Acad Sci 2008; 1142: 85-107.
95. Voon V, Thomsen T, Miyasaki JM, et al. Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. Arch Neurol 2007; 64: 212-216.
96. Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med 1999; 340: 757-763.
97. Pollak P, Tison F, Rascol O, et al. Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry 2004; 75: 689-695.
98. Fernandez HH, Trieschmann ME, Burke MA, Jacques C, Friedman JH. Long-term outcome of quetiapine use for psychosis among Parkinsonian patients. Mov Disord 2003; 18: 510-514.
99. Juncos JL, Roberts VJ, Evatt ML, et al. Quetiapine improves psychotic symptoms and cognition in Parkinson's disease. Mov Disord 2004; 19: 29-35.
100. Ondo WG, Tintner R, Voung KD, Lai D, Ringholz G. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Mov Disord 2005; 20: 958-963.
101. Rabey JM, Prokhorov T, Miniovitz A, Dobronevsky E, Klein C. Effect of quetiapine a double-blind in psychotic Parkinson's disease patients: labeled study of 3 months' duration. Mov Disord 2007; 22: 313-318.
102. Devos D, Dujardin K, Poirot I, et al. Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study. Mov Disord 2008; 23: 850-857.
103. Menza M, Dobkin RD, Marin H, et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 2009; 72: 886-892.
104. Okun MS, Fernandez HH. Will tricyclic antidepressants make a comeback for depressed Parkinson disease patients? Neurology 2009; 72: 868-869.
105. Klein C, Gordon J, Pollak L, Rabey JM. Clozapine in Parkinson's disease psychosis: 5-year follow-up review. Clin Neuropharmacol 2003; 26: 8-11.
106. Juri C, Chana P, Tapia J, Kunstmann C, Parrao T. Quetiapine for insomnia in Parkinson disease: results from an open-label trial. Clin Neuropharmacol 2005; 28: 185-187.
107. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004; 351: 2509-2518.
108. Friedman JH, Lannon MC. Clozapine-responsive tremor in Parkinson's disease. Mov Disord 1990; 5: 225-229.
109. Bonuccelli U, Ceravolo R, Salvetti S, et al. Clozapine in Parkinson's disease tremor: effects of acute and chronic administration. Neurology 1997; 49: 1587-1590.
110. Bennett JP, Jr, Landow ER, Schuh LA. Suppression of dyskinesias in advanced Parkinson's disease. II. Increasing daily clozapine doses suppress dyskinesias and improve parkinsonism symptoms. Neurology 1993; 43: 1551-1555.
111. Durif F, Debilly B, Galitzky M, et al. Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study. Neurology 2004; 62: 381-388.
112. Nieves AV, Lang AE. Treatment of excessive daytime sleepiness in patients with Parkinson's disease with modafinil. Clin Neuropharmacol 2002; 25: 111-114.
113. Limousin P, Krack P, Pollak P, et al. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 1998; 339: 1105-1111.
114. Witjas T, Baunez C, Henry JM, et al. Addiction in Parkinson's disease: impact of subthalamic nucleus deep brain stimulation. Mov Disord 2005; 20: 1052-1055.
115. Witjas T, Regis J, Delphini M, Peragut JC, Azulay JP. Dopamine dysregulation syndrome: impact of subthalamic chronic stimulation. Mov Disord 2007; 22 ( Suppl 16): S182.
116. Bandini F, Primavera A, Pizzorno M, Cocito L. Using STN DBS and medication reduction as a strategy to treat pathological gambling in Parkinson's disease. Parkinsonism Relat Disord 2007; 13: 369-371.
117. Molina JA, Sainz-Artiga MJ, Fraile A, et al. Pathologic gambling in Parkinson's disease: a behavioural manifestation of pharmacologic treatment? Mov Disord 2000; 15: 869-872.
118. Ardouin C, Voon V, Worbe Y, et al. Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation. Mov Disord 2006; 21: 1941-1946.
119. Witjas T, Kaphan E, Régis J, et al. Effects of chronic subthalamic stimulation on nonmotor fluctuations in Parkinson's disease. Mov Disord 2007; 22: 1729-1734.
120. Cersosimo MG, Piedimonte F, Raina GB, Micheli FE. Bilateral STN-DBS fails to improve non-motor fluctuations in a PD patient. Parkinsonism Relat Disord 2007; 13: 537-538.
121. Houeto JL, Mesnage V, Mallet L, et al. Behavioral disorders, Parkinson's disease and subthalamic stimulation. J Neurol Neurosurg Psychiatry 2002; 72: 701-707.
122. Lim SY, O'Sullivan SS, Kotschet K, et al. Dopamine dysregulation syndrome, impulse control disorders and punding after deep brain stimulation surgery for Parkinson's disease. J Clin Neurosci 2009; 16: 1148-1152.
123. Romito LM, Raja M, Daniele A, et al. Transient mania with hypersexuality after surgery for high-frequency stimulation of the subthalamic nucleus in Parkinson's disease. Mov Disord 2002; 17: 1371-1374.
124. Machado AG, Hiremath GK, Salazar F, Rezai AR. Fracture of subthalamic nucleus deep brain stimulation hardware as a result of compulsive manipulation: case report. Neurosurgery 2005; 57: E1318.
125. Smeding HMM, Speelman JD, Koning-Haanstra M, et al. Neuropsychological effects of bilateral STN stimulation in Parkinson disease: a controlled study. Neurology 2006; 66: 1830-1836.
126. Lu C, Bharmal A, Suchowersky O. Gambling and Parkinson disease. Arch Neurol 2006; 63: 298.
127. Morgan JC, diDonato CJ, Jenkins PD, Sethi KD. Self-stimulatory behaviour associated with deep brain stimulation in Parkinson's disease. Mov Disord 2006; 21: 283-285.
128. Smeding HMM, Goudriaan AE, Foncke EMJ, Schuurman PR, Speelman JD, Schmand B. Pathological gambling after bilateral subthalamic nucleus stimulation in Parkinson disease. J Neurol Neurosurg Psychiatry 2007; 78: 517-519.